Moderna CEO Stéphane Bancel received an annual compensation package worth $19.87 million last year, the largest he’s ever ...

CompanyOverview\|NASDAQ:MRNA] The CEO of Moderna Inc. (NASDAQ: MRNA) just purchased $5 million of stock in the open market.

The surge in MRNA stock comes after some SEC filings show that company insiders bought shares worth $6 million.

Moderna (MRNA) stock is climbing 8% after the drug maker won a key court case and its CEO bought shares on the open market.

Five years after the start of the pandemic, the fight over who owns the underlying technologies that made the Covid-19 ...

Despite high R&D spending and cash burn, Moderna aims for breakeven by 2028, driven by new vaccine opportunities. Explore ...

Moderna (MRNA) stock in focus as the company aims a 2027 marketing nod for Merck (MRK) partnered skin cancer vaccine. Read ...

Shares of the American pharmaceutical company Moderna (MRNA) climbed over 8% in pre-market trading following strategic ...

CEO Stephane Bancel has bought stock for the first time on the open market since he was named the top executive in October ...

But in 2025, Moderna aims to reduce cash cost expenses by $1 billion, CEO Stéphane Bancel said at the J.P. Morgan Healthcare Conference in January. The company will report its 2024 full-year ...

Last night, two purchases of Moderna’s stock by a firm controlled by MRNA CEO Stephane Bancel were reported. Bancel’s company, called Boston Biotech Ventures, bought 102,821 shares for an ...

Moderna CEO Stéphane Bancel deflected concerns about the new presidential administration's potential impact on life sciences and the appointment of vaccine skeptic Robert F. Kennedy Jr. as U.S ...